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in Neurodegenerative DisordersStem cells and their derivatives show tremendous potential for treating many disorders, including neurode-
generative diseases. We discuss here the challenges and potential for the translation of stem-cell-based
approaches into treatments for Parkinson’s disease, Huntington’s disease, and amyotrophic lateral
sclerosis.Introduction
‘‘Neurodegenerative disease’’ is a term used for a wide range of
acute and chronic conditions in which neurons in the brain
and spinal cord die. In these disorders, there is a core loss of
cells with a secondary population of ‘‘at risk’’ cells that may
succumb to the ongoing disease process, possibly driven or
exacerbated by a local inflammatory response. Stem-cell-based
therapies could potentially be beneficial by acting though several
mechanisms:
cell replacement, where transplants of cells are given to
directly replace those that are lost;
trophic support, where the cells are used to promote survival
of affected neurons and endogenous repair of the diseased
brain areas;
modulation of inflammation, which may be involved in the
disease process.
Any stem-cell-based approach for treating a neurodegenera-
tive disorder must be proven to work through one or more of
these mechanisms. No application in patients can be justified
on the basis that there is no alternative effective therapy if that
new experimental treatment has neither proven efficacy in the
laboratory nor any evidence to show a mechanism of action.
Trials showing safety alone without any scientific grounds for
their use are unethical. Here, we discuss the clinical translation
of stem cells in the treatment of three neurodegenerative disor-
ders: Parkinson’s disease (PD), Huntington’s disease (HD), and
amyotrophic lateral sclerosis (ALS). Comprehensive reviews
covering this topic have been published and are recommended
for further reading (see Table 1).
PD causes deficits in the control of movement secondary to
the degeneration of the dopaminergic nigrostriatal pathway,
but other dopaminergic and nondopaminergic systems are
also affected, with the development of many nonmotor prob-
lems. Whereas many motor features respond rather well to
dopaminergic medication and deep brain stimulation, effective
therapies for the nonmotor symptoms, such as dementia, are
lacking, and the progression of the disease is not slowed by
available treatments. In experimental clinical trials, transplants
of human fetal ventral mesencephalic tissue (containing devel-
oping nigral dopaminergic cells) can produce dramatic motor
improvements in some patients. Stem cell transplants should
be able to, in theory, help patients with PD by either replacing
the dopaminergic neurons or restoring and maintaining the
integrity of the nigrostriatal pathway through the release of
trophic factors. Stem cells can only be said to be curative ifthey (1) differentiate into appropriate midbrain dopaminergic
neurons and (2) integrate and send axons into areas with dopa-
minergic axon and synapse loss. No uncontrolled cell prolifera-
tion should occur, as this would pose a tumor risk. Based on the
available data, stem cells have the potential to help restore or
preserve striatal dopaminergic innervation; however, there are
few cell differentiation protocols that enable derivation of human
dopaminergic neurons with an authentic midbrain phenotype.
HD is an autosomal dominant disease that causes cellular
dysfunction and loss at numerous central nervous system
(CNS) sites including the striatum. The disease is fatal and is
characterized by chorea, psychiatric problems, and progres-
sive dementia. There is currently no effective treatment.
Reparative strategies for HD using cell replacement or trophic
factor support have concentrated on the striatum. Preclinical
studies in rodents and nonhuman primates have suggested
that intra-striatal transplants of fetal striatal tissue may have
restorative effects. While the clinical translation of these
studies in small Phase I trials has not resulted in the types
of dramatic improvements as seen for PD, there are some
early data suggesting that intra-striatal implants of human fetal
striatal allografts can ameliorate some aspects of the disease.
More preclinical work remains to be done, and the final
outcome of the already-initiated human transplant studies
needs to be assessed before considering additional clinical
trials for HD. With regard to stem cell transplants, there is
some evidence that neural progenitor cells can ameliorate
functional deficits in animal models of HD, perhaps through
the generation of astrocyte support cells and the release of
growth factors.
ALS causes the dysfunction and degeneration of motor
neurons in the spinal cord, cerebral cortex, and brainstem,
leading to rapidly progressing muscle weakness and death
within a few years of onset. No effective treatment exists. To
date, there is no proof-of-concept study demonstrating that
cell therapy can reduce the symptoms or extend life in people
affected with ALS. The most discussed use of stem cells is to
replace dying motor neurons in the brain and spinal cord.
However, there are major technical hurdles to overcome
including the delivery of cells to all of these sites and the require-
ment of axonal growth over long distances to the muscles.
Because glial cells may also contribute to the pathology in
ALS, leading to a secondary loss of neurons, a more practical
approach may be to provide stem-cell-derived astrocytes to de-
generating regions to protect dying motor neurons. Combining
these approaches with the delivery of growth factors may lead
to further neuroprotection. However, the progression of motorCell Stem Cell 10, 151–155, February 3, 2012 ª2012 ISSCR 151
Table 1. Recommended Additional Reading
Disease Review Articles
General overview Lindvall and Kokaia (2010)
Parkinson’s disease Arenas (2010); Lindvall and Kokaia (2009);
Tsui and Isacson (2011); Wijeyekoon and
Barker (2009)
Huntington’s disease Clelland et al. (2008); Kelly et al. (2009);
Kim et al. (2008)
Amyotrophic lateral
sclerosis
Hedlund et al. (2007); Mazzini et al.
(2009); Nayak et al. (2006); Suzuki and
Svendsen (2008); Thonhoff et al. (2009)
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and the careful consideration of how such processes may influ-
ence the survival of transplanted cells and the outcome of neu-
roprotective approaches is needed.
Details of Current State of Knowledge: Unmet Needs
and Prioritized Target Indications
Preclinical Models
Animal models of PD concentrate on lesions of the nigrostriatal
dopaminergic pathway (e.g., by 6-hydroxydopamine, MPTP,
and rotenone) and studies of sensorimotor functions. While this
is a useful starting point, these models do not imitate the clinical
disorder, which has many nonmotor and motor features with
nondopaminergic, extranigral pathologies. Nevertheless, these
dopaminergic lesion models are useful in evaluating the utility
of dopaminergic therapies such as stem cell grafts. Attempts
to develop transgenic models of PD have been pursued in recent
years, but these also represent useful but partial models of the
core pathologies.
The fact that HD is fully transmitted through a family gene
mutation has allowed transgenic models to be developed.
Several mousemodels of HD exist, but overall cell loss is limited,
and thus the use of transgenic mice for neuronal replacement
has met with limited success. However, all current transgenic
HD models can serve, to an extent, as experimental paradigms
for studying the possible trophic actions of stem cells, and
a delay in disease-like signs in these models would serve as
a useful outcome measure. For the replacement of cells or
neurons lost in the HD circuitry, excitotoxic/metabolic models
likely serve as more direct tests of the restorative potential of
cell grafts.
The primary animal model of ALS involves the overexpression
of mutated superoxide dismutase gene one (SOD1). Mice, rats,
or pigs expressing this mutation show no phenotype until young
adult ages are reached, at which time motor neurons gradually
die in the ventral spinal cord, leading to paralysis and death.
This progression is accompanied by inflammation. While very
accurately portraying the motor neuron loss seen in patients
with an SOD1 mutation, it is unclear how this model relates to
cases of the much more common sporadic ALS, in which the
SOD1 gene is unaffected.
Clinical Studies
Clinical trials using stem cells or their derivatives have not been
performed thus far for PD or HD. Following the intra-striatal
transplantation of human fetal mesencephalic tissue, which is
rich in dopaminergic neuroblasts, the dopaminergic neurons152 Cell Stem Cell 10, 151–155, February 3, 2012 ª2012 ISSCRthat form from the transplanted tissue reinnervate the dener-
vated striatum and become functionally integrated, restoring
striatal dopamine release and, for some PD patients, giving
rise to clear clinical improvement for over a decade. A subgroup
of transplanted patients developed troublesome involuntary
movements (dyskinesias), probably due to graft-derived striatal
serotonergic hyperinnervation or uneven distribution of the grafts
across the striatal complex. Grafts of human fetal striatal tissue
placed in the striatum of patients with mild HD have, in some
cases, given rise to long-term functional benefit for both motor
and cognitive features.
Hematopoietic and mesenchymal stem cells have both been
delivered to ALS patients to alter the inflammatory environment
and were reported to provide either no or some clinical benefit.
However, the preclinical data regarding safety, dosage, long-
term survival, differentiation, and functional efficacy are insuffi-
cient, and without a control group, the clinical evidence of
improvement is weak. It is important to note, however, that no
serious side effects were observed after injecting cells into the
spinal cord of ALS patients. More preclinical studies are needed
prior to further patient applications. Recently, neural stem cells
that were expanded from human fetal spinal cord tissue were
transplanted into the spinal cord of ALS patients as part of
a new FDA-approved Phase I trial. The rationale for this study
is not motor neuron or astrocyte replacement. Rather, the new
cells may form interneurons, which might affect motor neuron
output through poorly understood presynaptic mechanisms
and perhaps release growth factors to protect the remaining
motor neurons.
Cells Used
For PD, cells with the properties of dopaminergic neuroblasts
have been generated in vitro for preclinical transplantation
from stem cells of several different sources and species,
including humans. For example, they have been derived from
embryonic stem cells (ESCs), therapeutically cloned ESCs,
neural stem cells (NSCs) and progenitors from the embryonic
ventral mesencephalon, adult NSCs from the subventricular
zone, and fibroblast-derived induced pluripotent stem cells
(iPSCs). The yield of dopaminergic neuroblasts with the correct
substantia nigra phenotype can be increased by improved
differentiation protocols that utilize specific transcription factors
that determine mesencephalic dopaminergic neuron specifica-
tion or maturation during normal development.
For HD, attempts to generate striatal cells for transplantation
from NSCs expanded in vitro face a challenge in that pro-
longed propagation in the presence of growth factors may
impair the maintenance of a proper regional phenotype.
Recently, a multistep protocol was established that permits
the generation of striatal neurons from human ESCs. Upon
transplantation into quinolinic acid-lesioned rats, these cells
differentiated into DARPP32+ neurons and extended axons
into the host fiber tracts. However, despite the fact that the
cells were committed to a neural lineage, the grafts exhibited
massive proliferation, resulting in overgrowth, indicating the
necessity for a better control of donor cell differentiation after
transplantation.
Motor neurons and astrocytes, which are potentially useful for
preclinical applications for ALS, have been generated in vitro
from mouse and human ESCs and iPSCs and from human fetal
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precursors and neuroblasts established functional synapses
with muscle fibers in vitro and, in a few cases, extended axons
to ventral roots after transplantation into the spinal cord of
adult rats with motor neuron injury. However, such axon
targeting requires the presence of multiple complex factors,
including GDNF, within the fiber tracts to attract donor axons.
In recent experiments, mouse ESC-derived motor neurons
that were transplanted into transected tibial nerves of adult
mice established normal motor units and attenuated muscle
atrophy. The main problem with this method is how to regulate
the function of these motor neurons to affect movement
when they are placed within the nerve rather than the spinal
cord. While the death of motor neurons in ALS leads to paralysis,
dysfunctional astrocytes may also play a role in the overall
health and survival of sick motor neurons. Therefore, new strat-
egies to transplant stem-cell-derived astrocytes that could
protect dying motor neurons in ALS are also underway in many
laboratories.
Future Directions
Preclinical Studies
Human stem-cell-derived dopaminergic neuroblasts, which will
be required for patient applications, can survive in animal
models of PD, and, after maturation, exert functional effects.
However, some properties of stem-cell-derived dopaminergic
neurons that are fundamental for successful clinical translation
need to be confirmed in further studies, including evidence
that they can substantially reinnervate the striatum, restore
dopamine release in vivo, and markedly improve deficits that
resemble the symptoms experienced by PD patients. Experi-
mental work establishing these properties remains to be
performed before a human stem-cell-derived dopaminergic
neuroblast can be selected as a candidate cell for patient
application. More specifically, these cells should be tested in
a range of appropriate animal models, which in the first instance
will be the unilateral 6-hydroxydopamine lesion model of PD
in rats. The cells must be shown to survive long-term and
differentiate into the appropriate neuronal phenotype, i.e.,
midbrain doepaminergic neurons. Ongoing cell division must
not be present beyond 1–2 months after transplantation, and
the migration pattern of the cells should be defined. The con-
nectivity of cells to the host should be demonstrated using
standard immunohistochemical staining and in selected
cases be combined with anterograde and retrograde tracers.
A major portion of the striatum (>50%) should be evenly inner-
vated by graft-derived dopaminergic fibers. The ability of the
grafted cells to mediate sustained functional behavioral effects
in the animal model of PD must be shown by the following ways:
drug-induced rotation with a 100% reduction in amphet-
amine-induced rotation, which can be achieved by relatively
low numbers of dopaminergic cells (300) as is seen with
fetal mesencephalic tissue grafts;
significant recovery in performance in stepping, placing, or
cylinder tests in rats; and
the characterization of any changes in skilled reaching as
compared with the limits of efficacy using primary fetal
mesencephalic tissue grafts.For a cellular replacement approach to HD, it must be shown
that the grafted cells survive long-term in appropriate animal
models. The cells should differentiate into medium spiny
striatal projection neurons. When integrated into the brain, the
transplant should contain at least 30%–50% medium spiny
neurons as seen for transplants of cells derived from the
fetal ganglionic eminence. The migration pattern of the cells
should be known in addition to their connectivity to the host.
Ongoing cell division must not be present beyond 1–2 months
after transplantation. The grafted cells should be able to
induce behavioral improvements, and this functional recovery
should be sustained. This should involve beneficial effects
on the following deficits in animals with unilateral striatal
lesions:
paw reaching with the contralateral paw; and
poor performance on tasks of sensorimotor integration such
as contralateral neglect or a lateralized choice reaction time
task;
and should provide beneficial effects in bilaterally lesioned
animals with respect to:
normalization of locomotor activity; and
alleviation of deficits in a relevant cognitive task sensitive to
fronto-striatal dysfunction, such as delayed alternation.
For neuronal replacement therapy for ALS, the stem cells
must be competent to make functional motor neurons. This
generally requires ESCs or iPSCs as the source and increases
the risk of teratoma formation. Once the cells have been char-
acterized in vitro, they must be tested in vivo and shown to be
able to survive long-term at multiple CNS sites, integrate into
existing spinal cord neural circuitries, and receive appropriate
regulatory input and extend their axons over long distances to
reinnervate muscles. Finally, the transplanted motor neurons
must induce a clear functional benefit. While the SOD1
models provide a good preclinical base for moving these
types of studies forward, the environment of this model may
not be representative of that found in sporadic human ALS
patients. Therefore, new genetic models or models based
on motor neuron lesions using toxins should also be
considered.
The transplantation of stem cells for increased neuroprotec-
tion through the production of healthy astrocytes and/or the
release of neurotrophic molecules, the modification of the
inflammatory environment, or the generation of interneurons
is a more realistic near-term clinical goal for ALS. Preclinical
data must show the protection of motor neurons in the
SOD1 model and/or other motor neuron lesion models using
the strategy suggested for patients. Ideally, this should be
associated with functional improvement in the animals,
although simply protecting the motor neurons in these animal
models may be enough evidence to support moving forward to
the clinic, because these models clearly do not represent
sporadic ALS.
Clinical Studies
To be clinically competitive as a treatment for PD, stem-cell-
based dopaminergic cell replacement therapy must induce the
substantial (at least 50%–70%) amelioration of motor symptomsCell Stem Cell 10, 151–155, February 3, 2012 ª2012 ISSCR 153
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are carefully selected and the dose and site of implantation of the
dopaminergic cells are based on preoperative imaging. Strate-
gies to prevent the occurrence of graft-induced dyskinesias
following cell therapy must be developed, e.g., by minimizing
the number of serotonergic neuroblasts in the transplant
material and by distributing the dopaminergic neuroblasts
evenly over the striatum.
The use of stem-cell-derived neurons for replacement in HD is
on less secure footing, given that it is still unclear whether
primary allografts of fetal striatal tissue provide substantial and
prolonged clinical benefits to patients with HD. Nevertheless,
there is sufficient data from open-label studies to suggest that
transplants containing striatal tissue can ameliorate and reverse
some aspects of the disease. As such, stem-cell-derived trans-
plants for HD could be useful in two major ways: (1) by replacing
lost striatal projection neurons; and (2) by providing a local
source of neurotrophic factors to support this same population.
Stem cells may be capable of doing both of these functions at
the same time. The successful administration of stem cell trans-
plants will critically depend on them being implanted at the
optimal stage of the disease course, which is likely to be in early
stage patients.
Motor neuron replacement in ALS will probably be attempted
first at the level of the spinal cord. These initial studies will clearly
be ‘‘proof of concept,’’ be limited to a few spinal cord segments,
and must be based upon extensive preclinical data. These
studies need to be designed to show that the motor neurons
survive transplantation without forming teratomas, that they
can project axons into the ventral roots, and that some reach
the muscle and make connections. The challenge will be that
the disease progresses so rapidly that the patient may die before
the growing axons reach their target.
Cell Sources or Targets
After the transplantation of stem-cell-derived dopaminergic
neuroblasts and their subsequent maturation, they must exhibit
the properties of substantia nigra neurons to induce substantial
benefit for treating PD. It must be possible to grow the cells
in vitro in sufficient numbers to achieve a level of engraftment
that makes those cells useful in the clinical setting. The definition
of a dopaminergic nigral neuron derived from stem cell
sources includes the expression by immunohistochemistry of
phenotypic markers typical for those cells and the appropriate
expression profiles of genes and transcription factors that
define that specific region of the brain during normal nigral
development. The cells need to exhibit excitability using appro-
priate neurophysiological measures and dopamine release in
response to standard in vitro stimuli. All cell types in the cultures
need to be identified, especially the number of nonnigral
dopaminergic neurons, serotonergic neurons, other nondopami-
nergic neurons, glial elements, undifferentiated precursor/stem
cells, and, in the case of ESC- and iPSC-derived preparations,
nonneural cells. Recently, it has become possible to directly
convert fibroblasts into functional ‘‘induced’’ neurons (iNs),
including midbrain dopaminergic neurons. It remains to be
explored to what extent iNs can contribute to functional restora-
tion in models of PD.
For HD, the cells grown in vitro must differentiate into striatal
projection neurons (DARPP32+/GABA+) with a degree of effi-154 Cell Stem Cell 10, 151–155, February 3, 2012 ª2012 ISSCRcacy that would make translation to the clinic practical. The
proportion of other types of neurons should be determined using
markers for striatal interneuron phenotypes (which may be crit-
ical for the grafts to achieve optimal function), in addition to
markers of nonstriatal phenotypes (which may be considered
to be contaminants). The definition of a striatal projection neuron
includes the expression of typical phenotypic markers by immu-
nohistochemistry, the profiles of genes/transcription factors that
define that brain region during normal striatal development, and
at least some of the receptor subtypes and neuropeptides typi-
cally found in striatal projection neurons. The cells should be
able to release GABA and exhibit the excitability properties of
neurons.
For ALS, the nature of the donor cells to be used for transplan-
tation is still open to discussion. Whereas motor neuron replace-
ment represents an ideal target, successful in vivo cell delivery,
integration both into the motor cortex and across multiple levels
along the anteroposterior axis, and targeted axon outgrowth
currently pose insurmountable challenges. For such a neuronal
replacement strategy, motor neuron progenitors would have to
be delivered at a still immature, migratory stage to enable the
donor cells to actively infiltrate the motor cortex and the ventral
columns of the spinal cord and brainstem. Considering the
recently discovered non-cell-autonomous effects of astrocytes
from SOD1 mutants and sporadic variants on wild-type motor
neurons, ALS might also represent a candidate disease for glial
transplantation. However, further studies in animal models are
required to explore whether wild-type astrocytes or glial cells
engineered to express neurotrophic factors can home in on
motor neuron territories and protect host cells from disease-
related damage or death.ACKNOWLEDGMENTS
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